Printer Friendly

Clarus Ventures Promotes Scott Requadt to Managing Director.

CAMBRIDGE, Mass. and FOSTER CITY, Calif., Jan. 6, 2015 /PRNewswire/ -- Clarus Ventures, a leading life science investment firm, announced today the promotion of Scott Requadt to Managing Director.

Scott joined the firm as a Principal at Clarus' Cambridge office in 2005, and was promoted to Partner in 2010. He has led or co-led several Clarus investments, including TYRX, Intercept and Edev, as well as the acquisitions of royalty interests in Lexiscan and Imbruvica. He is currently a Director of Edev, was a Director of TYRX (acquired by Medtronic), and has been a Board Observer on several other Clarus investments. Scott joined Clarus from TransForm Pharmaceuticals where he was responsible for business development, corporate development and legal activities. Prior to TransForm, Scott was an M&A attorney at Davis Polk & Wardwell. He holds a B.Com (Economics & Finance) from McGill University, a law degree from University of Toronto, and an MBA from Harvard Business School, where he was a Baker Scholar.

"This promotion recognizes Scott's many contributions over the past decade, as well as his leadership abilities for the future growth of our firm," said Nicholas Galakatos, Managing Director and a co-founder of Clarus Ventures.

"Scott's success in structuring and executing on innovative risk-sharing partnerships with pharma partners has been a key value creator for our firm," added Nicholas Simon, Managing Director and a co-founder of Clarus Ventures.

"I'm excited to continue to work with the terrific team at Clarus as we continue to invest the Clarus Funds," noted Scott Requadt.

About Clarus Ventures Clarus Ventures is a leading global investment firm dedicated to life sciences. Founded in 2005 by a team of accomplished investment and operating professionals, Clarus manages over $1.6 billion invested in more than 50 private and public companies in biotechnology, medical devices and diagnostics. In every investment, Clarus employs a hands-on philosophy and adheres to investment principles that are founded on core competencies in drug development, complex partnership structuring and the ability to adapt to an ever-changing investment landscape. Clarus strives to generate outstanding returns for its investors by identifying and financing innovative medicines that improve people's lives. Clarus has offices in Cambridge, MA, and Foster City, CA. For more information please visit,

Contact: Lena Evans, Russo Partners, LLC, (212) 845-4262,

To view the original version on PR Newswire, visit:</a>

SOURCE Clarus Ventures, LLC

COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 2015
Previous Article:Richard Sutton Joins Reader's Digest Association as Chief Revenue Officer.
Next Article:API Technologies Receives $7.3 Million Order for C4ISR Products.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters